What are the risks of hormonal replacement therapy of postmenopauzal women?;Jak je to s riziky hormonální náhradní terapie (hrt) u postmenopauzálních žen?

Diabetologie Metabolismus Endokrinologie Vyziva

Volumn 6, Issue 1, 2003, Pages 30-32

  Stárka, Luboslav ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Cardiovascular diseases; HRT; Mammary carcinoma; Risks; WHI study

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; FEMALE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 0037673237     PISSN: 12119326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Collins P. Clinical cardiovascular studies of hormone replacement therapy. Am J Cardiol 2002; 90: 30F-34F.
2. Ewies AA. Phytoestrogens in the management of the menopause: up-to-date. Obstet Gynecol Surv 2002; 57: 306-313.
3. Lemaitre RN, Heckbert SR, Psaty BM, Smith NL, Kaplan RC, Longstreth WT Jr.Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med. 2002;162:1954-1960.
4. Marceau I. Menopause: when hormone therapy goes along with quality of life. Rev Infirm 1996; 19-20: 64-68.
5. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002; 186: 325-334.
6. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replaceement therapy: scientific review. J Am Med Assoc 2002; 288: 872-881.
7. Pfeiffer AFH, Dören M, Reincke M. Vorläufige Stellungnahme der Komission Hormontoxikologie der Deutschen Gesellschaft für Endokrinologie ze den Ergebnissen der "Women Health Initiative" Studie. Endokrinologie Informationen 2002; 26: 78-79.
8. Robinson GE. Psychotic and mood disorders associated with the perimenopausal period. Epidemiology, aetiology and management. CNS Drugs 2001; 15: 175-184.
9. WHI (Writing Group for the Women's Health Iniciative Investigators). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002; 288: 321-333.
10. Wise PM, Dubal DB, Wilson ME, Rau SW, Böttner M. Mini-review: Neuroprotective effects of estrogen - new insights into mechanisms of action. Endocrinology 2001; 142: 969-973.